Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Deckers designs, markets, and distributes outdoor footwear under the Teva, Simple, and Ugg brands. The company operates through domestic and international segments, with a significant portion of sales derived from the Teva brand.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 |
|---|---|---|
| Net Sales | $18,244,000 | $87,644,000 |
| Gross Profit | $5,721,000 (31.4% margin) | $36,700,000 (41.9% margin) |
| Net Earnings (Loss) | $(1,275,000) | $2,638,000 |
| EPS (Basic/Diluted) | $(0.14) | $0.30 |
| Cash from Operations | N/A | $22,404,000 |
| Cash and Equivalents | $1,647,000 (as of Sep 30, 1999) | |
| Working Capital | $33,134,000 (as of Sep 30, 1999) | |
| Long-Term Debt | $2,007,000 (excluding current installments) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 34.6% in the third quarter and 14.0% for the nine-month period compared to 1998. Teva sales drove significant growth (up 79.5% in Q3), while Simple sales declined due to lower demand and reduced closeout volume.
- Profitability Turnaround: The company reported a net loss of $1.275 million for Q3 1999, a significant improvement from the $5.133 million loss in Q3 1998. For the nine-month period, the company swung from a $1.974 million loss in 1998 to a $2.638 million profit in 1999.
- Margin Expansion: Gross margin improved to 31.4% in Q3 (from 9.6% in 1998) and 41.9% for the nine months (from 36.1% in 1998). This was primarily due to the non-recurrence of significant inventory write-downs and product recall charges incurred in 1998.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 16.3% in Q3 and increased only 3.2% for the nine months, despite sales growth, resulting in a lower SG&A percentage of sales.
- Debt Reduction: The company significantly reduced its debt load, with net repayments of long-term debt totaling $19.3 million during the nine-month period.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 1999 Teva sales to exceed 1998 levels, though the annual growth rate may be lower than the nine-month pace due to fewer retailer incentives in the Q4 early delivery program. Ugg sales are expected to increase, while Simple sales are expected to decrease.
- Seasonality: Teva sales are concentrated in Q1 and Q2, while Ugg sales peak in Q4. Unseasonably warm weather in Q4 1999 poses a risk to Ugg demand.
- Legal Contingency: A $1.785 million judgment was entered against the company in May 1999 regarding a breach of non-disclosure. The company is appealing and does not anticipate a material adverse effect.
- Trade Risks: Potential exposure to European anti-dumping duties of 49.2% on certain Teva styles imported from China. If applied, this could result in up to $500,000 in prior duties and force a change in sourcing strategies.
- Year 2000 Compliance: The company has implemented Year 2000 compliant enterprise systems but continues to assess risks related to suppliers and customers. Estimated compliance costs are approximately $450,000 total.
- Strategic Agreements: A new Teva license agreement signed in June 1999 grants exclusive worldwide rights through 2004, with options to renew and acquire the brand. This required a $1 million cash payment and issuance of stock.
Investor Verification Checklist
- Verify the status of the appeal regarding the $1.785 million Montana judgment.
- Monitor the resolution of the Dutch Customs inquiry regarding anti-dumping duties on Teva footwear.
- Assess the impact of Q4 weather patterns on Ugg sales volume and inventory levels.
- Review the company's ability to maintain the tangible net worth covenant under its $50 million revolving credit facility.
- Track the execution of the new Teva license agreement and the associated marketing expenditure requirements.